Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2001

Open Access 01-12-2001 | Review

Surfactant gene polymorphisms and interstitial lung diseases

Authors: Panagiotis Pantelidis, Dr Srihari Veeraraghavan, Roland M du Bois

Published in: Respiratory Research | Issue 1/2001

Login to get access

Abstract

Pulmonary surfactant is a complex mixture of phospholipids and proteins, which is present in the alveolar lining fluid and is essential for normal lung function. Alterations in surfactant composition have been reported in several interstitial lung diseases (ILDs). Furthermore, a mutation in the surfactant protein C gene that results in complete absence of the protein has been shown to be associated with familial ILD. The role of surfactant in lung disease is therefore drawing increasing attention following the elucidation of the genetic basis underlying its surface expression and the proof of surfactant abnormalities in ILD.
Literature
1.
Griese M: Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J. 1999, 13: 1455-1476. 10.1034/j.1399-3003.1999.13f36.x.PubMedCrossRef
2.
3.
Gunther A, Schmidt R, Nix F, Yabut-Perez M, Guth C, Rosseau S, Siebert C, Grimminger F, Morr H, Velcovsky HG, Seeger W: Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur Respir J. 1999, 14: 565-573. 10.1183/09031936.99.14356599.PubMedCrossRef
4.
McCormack FX, King TE, Bucher BL, Nielsen L, Mason RJ: Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995, 152: 751-759.PubMedCrossRef
5.
van de Graaf EA, Jansen HM, Lutter R, Alberts C, Kobesen J, De Vries IJ, Out TA: Surfactant protein A in bronchoalveolar lavage fluid. J Lab Clin Med. 1992, 120: 252-263.PubMed
6.
Hamm H, Luhrs J, Rotaeche J, Costabel U, Fabel H, Bartsch W: Elevated surfactant protein A in bronchoalveolar lavage fluids from sarcoidosis and hypersensitivity pneumonitis patients. Chest. 1994, 106: 1766-1770.PubMedCrossRef
7.
Cormier Y, Israel-Assayag E, Desmeules M, Lesur O: Effect of contact avoidance or treatment with oral prednisolone on bronchoalveolar lavage surfactant protein A levels in subjects with farmer's lung. Thorax. 1996, 51: 1210-1215.PubMedPubMedCentralCrossRef
8.
Voss T, Schafer KP, Nielsen PF, Schafer A, Maier C, Hannappel E, Maassen J, Landis B, Klemm K, Przybylski M: Primary structure differences of human surfactant-associated proteins isolated from normal and proteinosis lung. Biochim Biophys Acta. 1992, 1138: 261-267. 10.1016/0925-4439(92)90002-5.PubMedCrossRef
9.
Hattori A, Kuroki Y, Katoh T, Takahashi H, Shen HQ, Suzuki Y, Akino T: Surfactant protein A accumulating in the alveoli of patients with pulmonary alveolar proteinosis: oligomeric structure and interaction with lipids. Am J Respir Cell Mol Biol. 1996, 14: 608-619.PubMedCrossRef
10.
Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, Shiratori M, Kuroki Y, Abe S: Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000, 162: 1109-1114.PubMedCrossRef
11.
Takahashi H, Kuroki Y, Tanaka H, Saito T, Kurokawa K, Chiba H, Sagawa A, Nagae H, Abe S: Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med. 2000, 162: 258-263.PubMedCrossRef
12.
McGrath DS, Goh N, Foley PJ, du Bois RM: Sarcoidosis: genes and microbes–soil or seed?. Sarcoidosis Vasc Diffuse Lung Dis. 2001, 18: 149-164.PubMed
13.
Avila JJ, Lympany PA, Pantelidis P, Welsh KI, Black CM, du Bois RM: Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol. 1999, 20: 106-112.PubMedCrossRef
14.
Gilchrist FC, Bunn C, Foley PJ, Lympany PA, Black CM, Welsh KI, du Bois RM: Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun. 2001, 2: 76-81. 10.1038/sj/gene/6363734.PubMedCrossRef
15.
Pantelidis P, Fanning GC, Wells AU, Welsh KI, du Bois RM: Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001, 163: 1432-1436.PubMedCrossRef
16.
Renzoni E, Lympany P, Sestini P, Pantelidis P, Wells A, Black C, Welsh K, Bunn C, Knight C, Foley P, du Bois RM: Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum. 2000, 43: 1633-1640. 10.1002/1529-0131(200007)43:7<1633::AID-ANR29>3.3.CO;2-0.PubMedCrossRef
17.
Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, Fabbri M, Hall I, Britton J, Johnston I, Di Giovine F: Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med. 2000, 162: 755-758.PubMedCrossRef
18.
Karinch AM, deMello DE, Floros J: Effect of genotype on the levels of surfactant protein A mRNA and on the SP-A2 splice variants in adult humans. Biochem J. 1997, 321 (Pt 1): 39-47.CrossRef
19.
DiAngelo S, Lin Z, Wang G, Phillips S, Ramet M, Luo J, Floros J: Novel, non-radioactive, simple and multiplex PCR-cRFLP methods for genotyping human SP-A and SP-D marker alleles. Dis Markers. 1999, 15: 269-281.PubMedPubMedCentralCrossRef
20.
Lin Z, deMello DE, Batanian JR, Khammash HM, DiAngelo S, Luo J, Floros J: Aberrant SP-B mRNA in lung tissue of patients with congenital alveolar proteinosis (CAP). Clin Genet. 2000, 57: 359-369. 10.1034/j.1399-0004.2000.570506.x.PubMedCrossRef
21.
Floros J, Veletza SV, Kotikalapudi P, Krizkova L, Karinch AM, Friedman C, Buchter S, Marks K: Dinucleotide repeats in the human surfactant protein-B gene and respiratory-distress syndrome. Biochem J. 1995, 305 (Pt 2): 583-590.CrossRef
22.
Glasser SW, Korfhagen TR, Perme CM, Pilot-Matias TJ, Kister SE, Whitsett JA: Two SP-C genes encoding human pulmonary surfactant proteolipid. J Biol Chem. 1988, 263: 10326-10331.PubMed
23.
Gelehrter TD, Collins FS: Population genetics and multifactor-ial inheritance. In: Principles of Medical Genetics, International Edition. Baltimore: Williams and Wilkins;. 1990, 49-68.
24.
Nogee LM, Wert SE, Proffit SA, Hull WM, Whitsett JA: Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med. 2000, 161: 973-981.PubMedCrossRef
25.
Lin Z, deMello DE, Wallot M, Floros J: An SP-B gene mutation responsible for SP-B deficiency in fatal congenital alveolar proteinosis: evidence for a mutation hotspot in exon 4. Mol Genet Metab. 1998, 64: 25-35. 10.1006/mgme.1998.2702.PubMedCrossRef
26.
Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001, 344: 573-579. 10.1056/NEJM200102223440805.PubMedCrossRef
27.
Lin Z, Pearson C, Chinchilli V, Pietschmann SM, Luo J, Pison U, Floros J: Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS. Clin Genet. 2000, 58: 181-191. 10.1034/j.1399-0004.2000.580305.x.PubMedCrossRef
28.
Kala P, Ten Have T, Nielsen H, Dunn M, Floros J: Association of pulmonary surfactant protein A (SP-A) gene and respiratory distress syndrome: interaction with SP-B. Pediatr Res. 1998, 43: 169-177.PubMedCrossRef
29.
Haataja R, Ramet M, Marttila R, Hallman M: Surfactant proteins A and B as interactive genetic determinants of neonatal respiratory distress syndrome. Hum Mol Genet. 2000, 9: 2751-2760. 10.1093/hmg/9.18.2751.PubMedCrossRef
30.
Weber B, Borkhardt A, Stoll-Becker S, Reiss I, Gortner L: Polymorphisms of surfactant protein A genes and the risk of bronchopulmonary dysplasia in preterm infants. Turk J Pediatr. 2000, 42: 181-185.PubMed
S1.
Varpela E, Tiilikainen A, Varpela M, Tukiainen P: High prevalences of HLA-B15 and HLA-Dw6 in patients with cryptogenic fibrosing alveolitis. Tissue Antigens. 1979, 14: 68-71.PubMedCrossRef
S2.
Freeburn RW, Kendall H, Dobson L, Egan J, Simler NJ, Millar AB: The 3'-untranslated region of tumor necrosis factor-alpha is highly conserved in idiopathic pulmonary fibrosis (IPF). Eur Cytokine Netw. 2001, 12: 33-38.PubMed
S3.
Morrison CD, Papp AC, Hejmanowski AQ, Addis VM, Prior TW: Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis. Hum Pathol. 2001, 32: 521-528. 10.1053/hupa.2001.24321.PubMedCrossRef
S4.
Pasturenzi L, Martinetti M, Cuccia M, Cipriani A, Semenzato G, Luisetti M: HLA class I, II, and III polymorphism in Italian patients with sarcoidosis. The Pavia-Padova Sarcoidosis Study Group. Chest. 1993, 104: 1170-1175.PubMedCrossRef
S5.
S6.
Hedfors E, Lindstrom F: HLA-B8/DR3 in sarcoidosis. Correlation to acute onset disease with arthritis. Tissue Antigens. 1983, 22: 200-203.PubMedCrossRef
S7.
Smith MJ, Turton CW, Mitchell DN, Turner-Warwick M, Morris LM, Lawler SD: Association of HLA-B8 with spontaneous resolution in sarcoidosis. Thorax. 1981, 36: 296-298.PubMedPubMedCentralCrossRef
S8.
Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J: HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 1997, 156: 1601-1605.PubMedCrossRef
S9.
Swider C, Schnittger L, Bogunia-Kubik K, Gerdes J, Flad H, Lange A, Seitzer U: TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. Eur Cytokine Netw. 1999, 10: 143-146.PubMed
S10.
Bogunia-Kubik K, Tomeczko J, Suchnicki K, Lange A: HLA-DRB1*03, DRB1*11 or DRB1*12 and their respective DRB3 specificities in clinical variants of sarcoidosis. Tissue Antigens. 2001, 57: 87-90. 10.1034/j.1399-0039.2001.057001087.x.PubMedCrossRef
S11.
Schurmann M, Bein G, Kirsten D, Schlaak M, Muller-Quernheim J, Schwinger E: HLA-DQB1 and HLA-DPB1 genotypes in familial sarcoidosis. Respir Med. 1998, 92: 649-652.PubMedCrossRef
S12.
Naruse TK, Matsuzawa Y, Ota M, Katsuyama Y, Matsumori A, Hara M, Nagai S, Morimoto S, Sasayama S, Inoko H: HLA-DQB1*0601 is primarily associated with the susceptibility to cardiac sarcoidosis. Tissue Antigens. 2000, 56: 52-57. 10.1034/j.1399-0039.2000.560107.x.PubMedCrossRef
S13.
Ishihara M, Ohno S, Ishida T, Naruse T, Inoko H: Genetic polymorphism in intron 6 of the LMP7 gene in Japanese and its association with sarcoidosis. Tissue Antigens. 1997, 50: 650-653.PubMedCrossRef
S14.
Ishihara M, Naruse T, Ohno S, Kawata H, Mizuki N, Yamagata N, Ishida T, Nose Y, Inoko H: Analysis of HLA-DM polymorphisms in sarcoidosis. Hum Immunol. 1996, 49: 144-146. 10.1016/0198-8859(96)82496-7.PubMedCrossRef
S15.
Maliarik MJ, Chen KM, Major ML, Sheffer RG, Popovich J, Rybicki BA, Iannuzzi MC: Analysis of HLA-DPB1 polymorphisms in African-Americans with sarcoidosis. Am J Respir Crit Care Med. 1998, 158: 111-114.PubMedCrossRef
S16.
Schurmann M, Lympany PA, Reichel P, Muller-Myhsok B, Wurm K, Schlaak M, Muller-Quernheim J, du Bois RM, Schwinger E: Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med. 2000, 162: 861-864.PubMedCrossRef
S17.
Foley PJ, Lympany PA, Puscinska E, Zielinski J, Welsh KI, du Bois RM: Analysis of MHC-encoded antigen-processing genes TAP1 and TAP2 polymorphisms in sarcoidosis. Am J Respir Crit Care Med. 1999, 160: 1009-1014.PubMedCrossRef
S18.
Foley PJ, Lympany PA, Puscinska E, Gilchrist F, Avila J, Thackray I, Pantelides P, du Bois RM: HLA-DPB1 and TAP1 polymorphisms in sarcoidosis. Chest. 1997, 111: 73S-PubMedCrossRef
S19.
Lympany PA, Petrek M, Southcott AM, Newman Taylor AJ, Welsh KI, du Bois RM: HLA-DPB polymorphisms: Glu 69 association with sarcoidosis. Eur J Immunogenet. 1996, 23: 353-359.PubMedCrossRef
S20.
Ishihara M, Ohno S, Mizuki N, Yamagata N, Ishida T, Naruse T, Kuwata S, Inoko H: Genetic polymorphisms of the major histocompatibility complex-encoded antigen-processing genes TAP and LMP in sarcoidosis. Hum Immunol. 1996, 45: 105-110. 10.1016/0198-8859(95)00167-0.PubMedCrossRef
S21.
Ishihara M, Ohno S, Ishida T, Naruse T, Kagiya M, Mizuki N, Maruya E, Saji H, Inoko H: Analysis of allelic variation of the TAP2 gene in sarcoidosis. Tissue Antigens. 1997, 49: 107-110.PubMedCrossRef
S22.
Maliarik MJ, Rybicki BA, Malvitz E, Sheffer RG, Major M, Popovich J, Iannuzzi MC: Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med. 1998, 158: 1566-1570.PubMedCrossRef
S23.
McGrath DS, Foley PJ, Petrek M, Izakovicova-Holla L, Dolek V, Veeraraghavan S, Lympany PA, Pantelidis P, Vasku A, Wells AU, Welsh KI, du Bois RM: ACE gene I/D polymorphism and sarcoidosis pulmonary disease severity. Am J Respir Crit Care Med. 2001, 164: 197-201.PubMedCrossRef
S24.
Pietinalho A, Furuya K, Yamaguchi E, Kawakami Y, Selroos O: The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J. 1999, 13: 723-726. 10.1183/09031936.99.13472399.PubMedCrossRef
S25.
Papadopoulos KI, Melander O, Orho-Melander M, Groop LC, Carlsson M, Hallengren B: Angiotensin-converting enzyme (ACE) gene polymorphism in sarcoidosis in relation to associated autoimmune diseases. J Intern Med. 2000, 247: 71-77. 10.1046/j.1365-2796.2000.00575.x.PubMedCrossRef
S26.
Furuya K, Yamaguchi E, Itoh A, Hizawa N, Ohnuma N, Kojima J, Kodama N, Kawakami Y: Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax. 1996, 51: 777-780.PubMedPubMedCentralCrossRef
S27.
Schurmann M, Reichel P, Muller-Myhsok B, Dieringer T, Wurm K, Schlaak M, Muller-Quernheim J, Schwinger E: Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis. J Intern Med. 2001, 249: 77-83. 10.1046/j.1365-2796.2001.00776.x.PubMedCrossRef
S28.
Takemoto Y, Sakatani M, Takami S, Tachibana T, Higaki J, Ogihara T, Miki T, Katsuya T, Tsuchiyama T, Yoshida A, Yu H, Tanio Y, Ueda E: Association between angiotensin II receptor gene polymorphism and serum angiotensin-converting enzyme (SACE) activity in patients with sarcoidosis. Thorax. 1998, 53: 459-462.PubMedPubMedCentralCrossRef
S29.
Arbustini E, Grasso M, Leo G, Tinelli C, Fasani R, Diegoli M, Banchieri N, Cipriani A, Gorrini M, Semenzato G, Luisetti M: Polymorphism of angiotensin-converting enzyme gene in sarcoidosis. Am J Respir Crit Care Med. 1996, 153: 851-854.PubMedCrossRef
S30.
Seitzer U, Swider C, Stuber F, Suchnicki K, Lange A, Richter E, Zabel P, Muller-Quernheim J, Flad HD, Gerdes J: Tumour necrosis factor-alpha promoter gene polymorphism in sarcoidosis. Cytokine. 1997, 9: 787-790. 10.1006/cyto.1997.0224.PubMedCrossRef
S31.
Takashige N, Naruse TK, Matsumori A, Hara M, Nagai S, Morimoto S, Hiramitsu S, Sasayama S, Inoko H: Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens. 1999, 54: 191-193. 10.1034/j.1399-0039.1999.540211.x.PubMedCrossRef
S32.
Ishihara M, Ohno S, Ishida T, Mizuki N, Ando H, Naruse T, Ishihara H, Inoko H: Genetic polymorphisms of the TNFB and HSP70 genes located in the human major histocompatibility complex in sarcoidosis. Tissue Antigens. 1995, 46: 59-62.PubMedCrossRef
S33.
Yamaguchi E, Itoh A, Hizawa N, Kawakami Y: The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis. Chest. 2001, 119: 753-761. 10.1378/chest.119.3.753.PubMedCrossRef
S34.
Foley PJ, Lympany PA, Fanning GC, Welsh KI, du Bois RM: TNF-alpha and lymphotoxin-alpha polymorphisms in sarcoidosis – no association. Thorax. 1997, 52: A64-CrossRef
S35.
Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y: The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med. 1999, 159: 2021-2023.PubMedCrossRef
S36.
Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KI, Bunce M, Weigl E, du Bois RM: CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 2000, 162: 1000-1003.PubMedCrossRef
S37.
Maliarik MJ, Chen KM, Sheffer RG, Rybicki BA, Major ML, Popovich J, Iannuzzi MC: The natural resistance-associated macrophage protein gene in African-Americans with sarcoidosis. Am J Respir Cell Mol Biol. 2000, 22: 672-675.PubMedCrossRef
S38.
Foley PJ, Mullighan CG, McGrath DS, Pantelidis P, Marshall S, Lympany PA, Welsh KI, du Bois RM: Mannose-binding lectin promoter and structural gene variants in sarcoidosis. Eur J Clin Invest. 2000, 30: 549-552. 10.1046/j.1365-2362.2000.00656.x.PubMedCrossRef
S39.
Niimi T, Tomita H, Sato S, Akita K, Maeda H, Kawaguchi H, Mori T, Sugiura Y, Yoshinouchi T, Ueda R: Vitamin D receptor gene polymorphism and calcium metabolism in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2000, 17: 266-269.PubMed
S40.
Niimi T, Tomita H, Sato S, Kawaguchi H, Akita K, Maeda H, Sugiura Y, Ueda R: Vitamin D receptor gene polymorphism in patients with sarcoidosis. Am J Respir Crit Care Med. 1999, 160: 1107-1109.PubMedCrossRef
S41.
Niimi T, Sato S, Tomita H, Yamada Y, Akita K, Maeda H, Kawaguchi H, Sugiura Y, Ueda R: Lack of association with interleukin-1 receptor antagonist and interleukin-1 beta gene polymorphisms in sarcoidosis patients. Respir Med. 2000, 94: 1038-1042. 10.1053/rmed.2000.0892.PubMedCrossRef
S42.
Schaaf BM, Seitzer U, Pravica V, Aries SP, Zabel P: Tumor necrosis factor-alpha-308 promoter gene polymorphism and increased tumor necrosis factor serum bioactivity in farmer's lung patients. Am J Respir Crit Care Med. 2001, 163: 379-382.PubMedCrossRef
S43.
Wu WS, McClain KL: DNA polymorphisms and mutations of the tumor necrosis factor-alpha (TNF-alpha) promoter in Langerhans cell histiocytosis (LCH). J Interferon Cytokine Res. 1997, 17: 631-635.PubMedCrossRef
Metadata
Title
Surfactant gene polymorphisms and interstitial lung diseases
Authors
Panagiotis Pantelidis
Dr Srihari Veeraraghavan
Roland M du Bois
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2001
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/rr163

Other articles of this Issue 1/2001

Respiratory Research 1/2001 Go to the issue

Meeting report

First Siena International Conference on Animal Models of Chronic Obstructive Pulmonary Disease, Certosa di Pontignano, University of Siena, Italy, September 30-October 2, 2001

Review

Lung surfactant in subacute pulmonary disease

Research

The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome

Review

The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease

Commentary

Growth factors in lung development and disease: friends or foe?

Research

Activation of macrophage nuclear factor-κB and induction of inducible nitric oxide synthase by LPS
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits